One third of TTP patients will experience a relapse within 30 days of initial treatment.4 Serial ADAMTS13 activity should be monitored monthly for 3 months, every 3 months for 1 year, and then every 6-12 months thereafter.¹

Dr. Bates is an assistant professor of emergency and internal medicine at the Penn State Milton S Hershey Medical Center.

Dr. Turner originally trained at the Medical University of South Carolina, is an EM intern at Hershey Medical Center in Hershey, PA.

References

1. Sukumar S, Lämmle B, et al. Thrombotic thrombocytopenic purpura: pathophysiology, diagnosis, and management. J Clin Med. 2021;10(3):536.
2. Kessler CS, Khan BA, et al. Thrombotic thrombocytopenic purpura: a hematological emergency. J Emerg Med. 2012;43(3):538-44.
3. Li XM, Mo XY, et al. Therapeutical plasma exchange for thrombotic thrombocytopenic purpura in the emergency department: A single center experience. Am J Emerg Med. 2021;46:556-9
4. Long B, Bridwell RE, et al. Evaluation and management of thrombotic thrombocytopenic purpura in the emergency department. J Emerg Med. 2021;61(6):674-82.
5. Stella CL, Dacus J, et al. The diagnostic dilemma of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in the obstetric triage and emergency department: lessons from 4 tertiary hospitals. Am J Obstet Gynecol. 2009;200(4):381-e1.
6. Stanley M, Killeen RB, et al. Thrombotic thrombocytopenic purpura. In:StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing;2022. Available at: https://www.ncbi.nlm.nih.gov/books/NBK430721/. Updated April 7, 2023. Accessed March 26, 2024.
7. Zheng XL, Vesely SK, et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020;18(10):2496-502.
8. Izquierdo CP, Mingot-Castellano ME, et al. Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura. Blood Adv. 2022;6(24):6219-27.